KYMR vs PTGX: Which Stock Is the Better Buy?
Kymera Therapeutics, Inc. and Protagonist Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — KYMR vs PTGX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Kymera Therapeutics, Inc. (KYMR) | Protagonist Therapeutics, Inc. (PTGX) | |
|---|---|---|
| Market cap | $6.7B | $6.9B |
| Revenue (latest FY) | $39.21M | $46.02M |
| Net income (latest FY) | $-311.35M | $-130.15M |
| Revenue growth (5y CAGR) | 2.9% | 10.0% |
| Net margin | -794.0% | -282.8% |
| Return on equity | -19.7% | -21.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full KYMR vs PTGX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open KYMR's full financials → Open PTGX's full financials →More comparisons
Frequently asked questions
Which is bigger, KYMR or PTGX?
Protagonist Therapeutics, Inc. is larger by market capitalization — $6.9B versus $6.7B.
Which grows faster, KYMR or PTGX?
Over the last five fiscal years, Protagonist Therapeutics, Inc. grew revenue faster — 10.0%/yr versus 2.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.